News

MediSure Canada Receives Health Canada Licence For Two New Best-In-Class Products

Jan 4, 2022 | Press Releases

New Blood Glucose Monitor and Rapid At-Home Vitamin D Deficiency Test Provides Innovative Solutions to Canadian Healthcare Needs

VANCOUVER, BC / ACCESSWIRE / January 4, 2022 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms, a medical device company, and a high complexity medical diagnostics laboratory – is pleased to announce its subsidiary, MediSure Canada, has received new Health Canada Medical Device Licences for MediSure healthcare products. This includes a Class 3 Medical Device Licence under the number 107186 for the commercialization of its next MediSure™ Empower Blood Glucose Monitoring System (“BGM“), and a Class 2 Medical Device Licence under the number 107206 for the commercialization of a Medisure™ Vitamin D Rapid Test (“Vitamin D Rapid Test“).

MediSure Canada, a wholly owned subsidiary, has over two decades of experience in the diabetic management healthcare industry. The Company is pleased to expand its product line and provide innovative solutions to Canadians living with diabetes. The latest BGM product augments the existing line by providing a system with state-of-the-art Bluetooth capabilities. It allows patients to instantly connect their health information to their phone through a lighter and more compact medical device.

This latest BGM product will provide doctors and Canadians with additional choices in their diabetic management planning. MediSure continues to see immense demand for its products due to its reputation for high-quality, affordable products. The Company is currently working to register the device with insurance providers; this step will make the product accessible through Canadians’ healthcare plans. MediSure anticipates rolling out its new BGM online and in pharmacies in late Q1 2022.

MediSure continues to expand beyond the diabetic industry with its recent MediSure™ Rapid Antigen Health Canada test submission and now the approval of its first ever Vitamin D Rapid Test. Vitamin D deficiency affects roughly 10% of Canadians, and it contributes to various adverse health effects such as heart disease, high blood pressure, and infections and immune system disorders. Vitamin D testing places a great toll on the healthcare system as patients are required to see their doctor and be referred for blood work. MediSure™ Vitamin D Rapid Test lowers the barriers to identifying this problem by creating the first fully at-home Vitamin D Rapid Test kit in Canada. Through the kits patients are able to receive a result on whether they have vitamin D deficiency without heading to the doctor’s office. These kits enable patients to act as better advocates and stewards of their healthcare. MediSure anticipates commercialization of this product in Q1 2022.

“MediSure has made immense progress since joining Empower,” said Steven McAuley, Chairman and CEO of Empower. “Through the capacity and leadership of our team, they’ve been able to double down on their sales, increase their research and development, and, most importantly, expand their ability to provide affordable and quality health management solutions.”

“The next-generation BGM product and Vitamin D test are amazing additions to the MediSure line,” added Mario Cortis, President of MediSure. “Canadians health is better served when they have access to top-quality tools, I’m proud we’re able to redeploy our experience in the diabetes industry to improve other healthcare needs.”

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT MEDISURE:

MediSure Canada is a Canadian medical device company dedicated to bringing value to the high cost of diabetes, both to patients and insurers. MediSure’s products are designed and manufactured with safety and durability in mind, meeting all ISO standards with world-class quality controls. Equipped with features that lead the industry in technology, MediSure’s products are designed to offer a user-friendly experience and an overall improved approach to diabetes management.

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Media:

Steven McAuley
CEO
s.mcauley@empowerclinics.com
604-789-2146

Investors:

Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s plans with respect to the offering of other Empower services and products; that the Company may be able to commercialize new MediSure products or any new medical devices. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company may be unable to enter into definitive agreements, or close transactions with respect to, proposed future clinic openings; that due diligence with respect to anticipated clinic openings and acquisitions may not be satisfactory to the Company; risks related to delays in permitting or construction; risks related to supply chains and access to labour; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for new clinics; general business, economic, competitive, political and social uncertainties; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

Categories